An Update on the Management of Rectal Neuroendocrine Neoplasms.
Endoscopic resection
Endoscopic ultrasound
Lymphovascular invasion
Rectal neuroendocrine tumours
Systemic therapies
Journal
Current treatment options in oncology
ISSN: 1534-6277
Titre abrégé: Curr Treat Options Oncol
Pays: United States
ID NLM: 100900946
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
accepted:
24
09
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
Rectal neuroendocrine neoplasms (NENs) are increasing in incidence. Most lesions are low grade, well-differentiated neuroendocrine tumours with good long term outcomes. However there is metastatic potential and resection offers the only option for a cure and in most cases should be offered to reduce the risk of metastases. Careful staging of rectal NENs should be performed prior to consideration of resection in order to ensure the appropriate technique is chosen, and reduce the risk of incomplete resection. Resection can be endoscopic or surgical, and selecting the appropriate resection technique relies on tumour characteristics such as size, grade, invasion into the muscularis propria, presence of lymph node involvement or of distal metastases. Some patients may require systemic therapies which may involve somatostatin analogues (SSAs), everolimus, tyrosine kinase inhibitors (TKIs), chemotherapy or peptide receptor radionuclide therapy (PRRT). Due the rarity of these tumours, much of the evidence is based on retrospective reviews or smaller cohort studies. This article is an update of the current evidence available to guide management.
Identifiants
pubmed: 39476215
doi: 10.1007/s11864-024-01267-4
pii: 10.1007/s11864-024-01267-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Basuroy R, Haji A, Ramage JK, Quaglia A, Srirajaskanthan R. Review article: the investigation and management of rectal neuroendocrine tumours. Aliment Pharmacol Ther. 2016;44(4):332–45.
doi: 10.1111/apt.13697
pubmed: 27302838
Srirajaskanthan R, Clement D, Brown S, Howard MR, Ramage JK. Optimising Outcomes and Surveillance Strategies of Rectal Neuroendocrine Neoplasms. Cancers (Basel). 2023;15(10):2766.
doi: 10.3390/cancers15102766
pubmed: 37345103
Abboud Y, Pendyala N, Le A, Mittal A, Alsakarneh S, Jaber F, Hajifathalian K. The Incidence of Rectal Neuroendocrine Tumors Is Increasing in Younger Adults in the US, 2001–2020. Cancers (Basel). 2023;15(21):5286.
doi: 10.3390/cancers15215286
pubmed: 37958459
Popa O, Taban SM, Pantea S, Plopeanu AD, Barna RA, Cornianu M, et al. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med. 2021;22(4):1179.
doi: 10.3892/etm.2021.10613
pubmed: 34475969
pmcid: 8406677
Cope J, Srirajaskanthan R. Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation? Curr Oncol Rep. 2022;24(3):257–63.
doi: 10.1007/s11912-021-01172-1
pubmed: 35084662
pmcid: 8885478
Masui T, Ito T, Komoto I, Uemoto S, Group JPS. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer. 2020;20(1):1104.
doi: 10.1186/s12885-020-07581-y
pubmed: 33189127
pmcid: 7666508
Fan J-H, Zhang Y-Q, Shi S-S, Chen Y-J, Yuan X-H, Jiang L-M, et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget. 2017;8(42):71699.
doi: 10.18632/oncotarget.17599
pubmed: 29069739
pmcid: 5641082
Das S, Dasari A. Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep. 2021;23(4):43.
doi: 10.1007/s11912-021-01029-7
pubmed: 33719003
pmcid: 8118193
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.
doi: 10.1200/JCO.2007.15.4377
pubmed: 18565894
Fine C, Roquin G, Terrebonne E, Lecomte T, Coriat R, Do Cao C, et al. Endoscopic management of 345 small rectal neuroendocrine tumours: a national study from the French group of endocrine tumours (GTE). United Eur Gastroenterol J. 2019;7(8):1102–12.
doi: 10.1177/2050640619861883
Rinke A, Ambrosini V, Dromain C, Garcia-Carbonero R, Haji A, Koumarianou A, et al. European neuroendocrine tumor society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours. J Neuroendocrinol. 2023;35(6):e13309.
doi: 10.1111/jne.13309
pubmed: 37345509
Ramage JK, De Herder WW, DelleFave G, Ferolla P, Ferone D, Ito T, et al. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):139–43.
doi: 10.1159/000443166
pubmed: 26730835
Panzuto F, Parodi MC, Esposito G, Massironi S, Fantin A, Cannizzaro R, et al. Endoscopic management of gastric, duodenal and rectal NETs: position paper from the italian association for neuroendocrine tumors (Itanet), Italian Society of Gastroenterology (SIGE), Italian Society of Digestive Endoscopy (SIED). Dig Liver Dis. 2024;56:589
Ma XX, Wang LS, Wang LL, Long T, Xu ZL. Endoscopic treatment and management of rectal neuroendocrine tumors less than 10 mm in diameter. World J Gastrointest Endosc. 2023;15(2):19–31.
doi: 10.4253/wjge.v15.i2.19
pubmed: 36925647
pmcid: 10011890
Inada Y, Yoshida N, Fukumoto K, Hirose R, Inoue K, Dohi O, et al. Risk of lymph node metastasis after endoscopic treatment for rectal NETs 10 mm or less. Int J Colorectal Dis. 2021;36(3):559–67.
doi: 10.1007/s00384-020-03826-1
pubmed: 33388960
Wang Z, Yu G, Li L, Qi S, Liu Q. A retrospective analysis of 32 small and well-differentiated rectal neuroendocrine tumors with regional or distant metastasis. Rev Esp Enferm Dig. 2023;115(6):336–7.
pubmed: 36281930
O’Neill S, Haji A, Ryan S, Clement D, Sarras K, Hayee B, et al. Nodal metastases in small rectal neuroendocrine tumours. Colorectal Dis. 2021;23(12):3173–9.
doi: 10.1111/codi.15978
pubmed: 34731512
Yu Q, Zhang Y, Su Y, Zhao Q, Xiong K, Zhang L, Fang H. Optimization of Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection Strategies for Rectal Neuroendocrine Tumors Within 20 mm. The American Surgeon™. 2024;90:1176. https://doi.org/10.1177/00031348241226722 .
Yang DH, Park Y, Park SH, Kim KJ, Ye BD, Byeon JS, et al. Cap-assisted EMR for rectal neuroendocrine tumors: comparisons with conventional EMR and endoscopic submucosal dissection (with videos). Gastrointest Endosc. 2016;83(5):1015–22; quiz 23-.e6.
Zhou C, Zhang F, We Y. Efficacy of endoscopic mucosal resection versus endoscopic submucosal dissection for rectal neuroendocrine tumors ≤10mm: a systematic review and meta-analysis. Ann Saudi Med. 2023;43(3):179–95.
doi: 10.5144/0256-4947.2023.179
pubmed: 37270677
pmcid: 10317491
Gao X, Huang S, Wang Y, Peng Q, Li W, Zou Y, et al. Modified Cap-Assisted Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors ≤10 mm: A Randomized Noninferiority Trial. Official journal of the American College of Gastroenterology | ACG. 2022;117(12):1982–9.
Matsuno K, Miyamoto H, Kitada H, Yoshimatsu S, Tamura F, Sakurai K, et al. Comparison of endoscopic submucosal resection with ligation and endoscopic submucosal dissection for small rectal neuroendocrine tumors: A multicenter retrospective study. DEN Open. 2023;3(1):e163.
doi: 10.1002/deo2.163
pubmed: 36176350
Takada K, Imai K, Yamada T, Ohata K, Kanesaka T, Nagami Y, et al. Efficacy of endoscopic submucosal resection with a ligation device for small rectal neuroendocrine tumor: study protocol of a multicenter open-label randomized control trial (BANDIT trial). BMC Gastroenterol. 2024;24(1):69.
doi: 10.1186/s12876-024-03130-0
pubmed: 38331727
pmcid: 10854141
Pan J, Zhang X, Shi Y, Pei Q. Endoscopic mucosal resection with suction vs. endoscopic submucosal dissection for small rectal neuroendocrine tumors: a meta-analysis. Scand J Gastroenterol. 2018;53(9):1139–45.
doi: 10.1080/00365521.2018.1498120
pubmed: 30193543
Wang FG, Jiang Y, Liu C, Qi H. Comparison between endoscopic submucosal dissection and transanal endoscopic microsurgery in early rectal neuroendocrine tumor patients: a meta-analysis. J Invest Surg. 2023;36(1):2278191.
doi: 10.1080/08941939.2023.2278191
pubmed: 37970828
Meier B, Albrecht H, Wiedbrauck T, Schmidt A, Caca K. Full-thickness resection of neuroendocrine tumors in the rectum. Endoscopy. 2020;52(1):68–72.
doi: 10.1055/a-1008-9077
pubmed: 31614372
Choi JS, Kim MJ, Shin R, Park JW, Heo SC, Jeong SY, et al. Risk factor analysis of lymph node metastasis for rectal neuroendocrine tumors: who needs a radical resection in rectal neuroendocrine tumors sized 1–2 cm? Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-023-14829-x
Torres N, El Moussaoui M, Basbous S, Fridman V, Borbath I, Deflandre J. Watch-an-wait strategy for multiple rectal neuroendocrine tumors with widespread invasion. Acta Gastroenterol Belg. 2023;86(4):563–5.
doi: 10.51821/86.4.10381
pubmed: 38240551
Zhao B, Hollandsworth HM, Lopez NE, Parry LA, Abbadessa B, Cosman BC, et al. Outcomes for a large cohort of patients with rectal neuroendocrine tumors: an analysis of the national cancer database. J Gastrointest Surg. 2021;25(2):484–91.
doi: 10.1007/s11605-020-04525-6
pubmed: 32016672
Stier MW, Chapman CG, Shamah S, Donboli K, Yassan L, Waxman I, Siddiqui UD. Endoscopic resection is more effective than biopsy or EUS to detect residual rectal neuroendocrine tumor. Endosc Int Open. 2021;9(1):E4-e8.
doi: 10.1055/a-1300-1017
pubmed: 33403229
pmcid: 7775810
Cheminel L, Lupu A, Wallenhorst T, Lepilliez V, Leblanc S, Albouys J, et al. Systematic resection of the visible scar after incomplete endoscopic resection of rectal neuroendocrine tumors. Am J Gastroenterol. 2024;119(2):378–81.
doi: 10.14309/ajg.0000000000002516
pubmed: 37734341
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.
doi: 10.1056/NEJMoa1316158
pubmed: 25014687
Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71(2):502–13.
doi: 10.1007/s12020-020-02475-2
pubmed: 33052555
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.
doi: 10.1200/JCO.2009.22.8510
pubmed: 19704057
Kim JY, Kim J, Kim YI, Yang DH, Yoo C, Park IJ, et al. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors. Sci Rep. 2024;14(1):4047.
doi: 10.1038/s41598-024-54599-4
pubmed: 38374188
pmcid: 10876978
Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, et al. Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. Neuroendocrinology. 2018;106(3):211–20.
doi: 10.1159/000477585
pubmed: 28554173
Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(11):1500–12.
doi: 10.1016/S1470-2045(20)30496-4
pubmed: 32966811
Garcia-Carbonero R, Benavent M, Fonseca PJ, Castellano D, Alonso T, Teule A, et al. A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107). Journal of Clinical Oncology. 2021;39(3_suppl):360-. https://doi.org/10.1200/JCO.2021.39.3_suppl.360
Chan J, Geyer S, Ou FS, Knopp M, Behr S, Zemla T, et al. LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET). Ann Oncol. 2023;34:S1292.
doi: 10.1016/j.annonc.2023.10.047
Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, et al. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)–a phase II non-randomised trial. Eur J Cancer. 2014;50(18):3107–15.
doi: 10.1016/j.ejca.2014.10.001
pubmed: 25454413
Gallo C, Rossi RE, Cavalcoli F, Barbaro F, Boškoski I, Invernizzi P, Massironi S. Rectal neuroendocrine tumors: current advances in management, treatment, and surveillance. World J Gastroenterol. 2022;28(11):1123–38.
doi: 10.3748/wjg.v28.i11.1123
pubmed: 35431507
pmcid: 8985485
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.
doi: 10.1056/NEJMoa1607427
pubmed: 28076709
pmcid: 5895095
Kong G, Grozinsky-Glasberg S, Hofman MS, Akhurst T, Meirovitz A, Maimon O, et al. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). Eur J Nucl Med Mol Imaging. 2019;46(3):718–27.
doi: 10.1007/s00259-018-4196-8
pubmed: 30343432
Li Y, Guo Y, Cheng Z, Tian C, Chen Y, Chen R, et al. Whole-exome sequencing of rectal neuroendocrine tumors. Endocr Relat Cancer 2023;30(9). https://doi.org/10.1530/ERC-22-0257
Duan X, Zhao M, Yin X, Mi L, Shi J, Li N, et al. Molecular typing and mutational characterization of rectal neuroendocrine neoplasms. Cancer Med. 2023;12(15):16207–20.
doi: 10.1002/cam4.6281
pubmed: 37387515
pmcid: 10469650
Li K, Liu Y, Han J, Gui J, Zhang X. The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review. Endocr J. 2023;70(2):197–205.
doi: 10.1507/endocrj.EJ22-0262
pubmed: 36403965